5-ethyl-6-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(piperidin-1-ylmethyl)benzofuran-4-carboxamide

ID: ALA4161444

Chembl Id: CHEMBL4161444

PubChem CID: 135332289

Max Phase: Preclinical

Molecular Formula: C32H44N4O5

Molecular Weight: 564.73

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CCc1c(N(CC)C2CCOCC2)cc2oc(CN3CCCCC3)cc2c1C(=O)NCc1c(OC)cc(C)[nH]c1=O

Standard InChI:  InChI=1S/C32H44N4O5/c1-5-24-27(36(6-2)22-10-14-40-15-11-22)18-29-25(17-23(41-29)20-35-12-8-7-9-13-35)30(24)32(38)33-19-26-28(39-4)16-21(3)34-31(26)37/h16-18,22H,5-15,19-20H2,1-4H3,(H,33,38)(H,34,37)

Standard InChI Key:  QPPMMEVJOAYDNF-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4161444

    ---

Associated Targets(Human)

EZH1 Tchem EZH1/SUZ12/EED/AEBP2/RBBP4 complex (29 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Pfeiffer (261 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 564.73Molecular Weight (Monoisotopic): 564.3312AlogP: 4.92#Rotatable Bonds: 10
Polar Surface Area: 100.04Molecular Species: NEUTRALHBA: 7HBD: 2
#RO5 Violations: 1HBA (Lipinski): 9HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 11.15CX Basic pKa: 8.49CX LogP: 2.87CX LogD: 1.74
Aromatic Rings: 3Heavy Atoms: 41QED Weighted: 0.36Np Likeness Score: -0.92

References

1. Lu B, Shen X, Zhang L, Liu D, Zhang C, Cao J, Shen R, Zhang J, Wang D, Wan H, Xu Z, Ho MH, Zhang M, Zhang L, He F, Tao W..  (2018)  Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma.,  (2): [PMID:29456795] [10.1021/acsmedchemlett.7b00437]

Source